Deep Track Capital ITCI Position
Exited6-Fund ConvergenceDeep Track Capital exited their position in Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
ITCI is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Lumateperone in 45 days (May 31, 2026), making the timing of Deep Track's position particularly relevant.
About Intra-Cellular Therapies Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Full company profile →Deep Track Capital ITCI Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -2,000,000 | $0 |
| Q1 2025 | Held | 2,000,000 | — | $263.8M |
| Q4 2024 | Increased | 2,000,000 | +399,307 | $167.0M |
| Q3 2024 | Increased | 1,600,693 | +62,771 | $117.1M |
| Q2 2024 | Increased | 1,537,922 | +37,922 | $105.3M |
| Q1 2024 | Decreased | 1,500,000 | -500,000 | $103.8M |
| Q4 2023 | Decreased | 2,000,000 | -600,000 | $143.2M |
| Q3 2023 | Increased | 2,600,000 | +1,051,748 | $135.4M |
| Q2 2023 | Decreased | 1,548,252 | -151,748 | $98.0M |
| Q1 2023 | New | 1,700,000 | +1,700,000 | $92.1M |
Frequently Asked Questions
Does Deep Track Capital own ITCI?
No. Deep Track Capital exited their position in Intra-Cellular Therapies Inc. (ITCI) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own ITCI?
6 specialist biotech hedge funds currently hold ITCI, including Avoro Capital Advisors, Perceptive Advisors, Deerfield Management and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy ITCI?
Deep Track Capital's position in ITCI was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's ITCI position increasing or decreasing?
Deep Track Capital completely exited their ITCI position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ITCICompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →